Email this article Management of giant cell tumor in the denosumab era. Literature review
- Authors: Tararykova A.A.1, Fedenko A.A.2, Musaev E.R.1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of the Russian Federation
- National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
- Issue: Vol 12, No 4 (2020)
- Pages: 11-21
- Section: EDITORIAL
- Published: 06.11.2020
- URL: https://sarbon.abvpress.ru/jour/article/view/10
- DOI: https://doi.org/10.17650/2070-9781-2020-12-4-11-21
- ID: 10
Cite item
Full Text
Abstract
The article represents a literature review of the giant cell tumor management based on the RANKL overexpression and according this use of the denosumab.Weconsidered the pathogenesis of giant cell tumor based on the process of osteoclastogenesis (RANK/RANKL) discovered in the 1990s and a new H3F3A driver mutation. The history, experience and results of the denosumab treatment, as well as the issues of evaluation and interpretation of the treatment response are represented.
Keywords
About the authors
A. A. Tararykova
N.N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of the Russian Federation
Author for correspondence.
Email: anastasiatararykova@gmail.com
ORCID iD: 0000-0002-5548-3295
24 Kashirskoe Shosse, Moscow 115478
Russian FederationA. A. Fedenko
National Medical Research Radiological Center of the Ministry of Health of the Russian Federation
ORCID iD: 0000-0003-4927-5585
3 2nd Botkinskiy Proezd, 125284 Moscow
Russian FederationE. R. Musaev
N.N. Blokhin National Medical Research Center of Oncology оf the Ministry of Health of the Russian Federation
ORCID iD: 0000-0002-1241-3019
24 Kashirskoe Shosse, Moscow 115478
Russian FederationReferences
Supplementary files
